RADIOSURGICAL TREATMENT OF RECURRENT GLIOBLASTOMA AND PROGNOSTIC FACTORS AFFECTING TREATMENT OUTCOMES

Authors

  • O.Ya. Glavatskyi Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine
  • A.B Griazov Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine
  • O.Yu. Chuvashova Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine
  • I.V. Kruchok Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine
  • A.A. Griazov Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine
  • H.V. Khmelnytskyi Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine
  • I.M. Shuba Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine
  • V.A. Stuley Igor Sikorsky Kyiv Polytechnic Institute
  • O.V. Zemskova Romodanov Neurosurgery Institute of the National Academy of Medical Sciences of Ukraine

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-4.18920

Keywords:

glioblastoma, malignant glioma, neurosurgical procedures, radiosurgery, recurrence., survival

Abstract

Background: Glioblastoma (GBM) is the most prevalent malignant tumor of the brain in adults with the inherent aggressive behavior and high recurrence rate. The stereotactic radiosurgery (SRS) is currently considered as one of the effective modalities for GBM treatment allowing for the improvement of survival with the acceptable toxicity level. Aim: To assess the effects of various factors on the survival of GBM patients following SRS. Patients and Methods: We retrospectively reviewed treatment outcomes of 68 patients who received SRS for recurrent GBM treatment in 2014–2020. SRS was delivered with Trilogy linear accelerator (6 MeV). The area of recurrent tumor/continued tumor growth was irradiated. For the treatment of the primary GBM, the adjuvant radiotherapy was provided at the standard fractionated regimen with the total boost dose of 60 Gy divided to 30 fractions (Stupp’s protocol) in the setting of the concomitant chemotherapy with temozolomide. 36 patients then received temozolomide as the maintenance chemotherapy. SRS for the treatment of recurrent GBM was provided at a boost dose of 20.2 Gy on average being delivered into 1–5 fractions with average single dose of 12.4 Gy. The survival was analyzed by the Kaplan—Meier method with a log-rank test used for assessing the impact of the independent predictors on the survival risks. Results: The median overall survival (OS) was 21.7 months (95% confidence interval (CІ) 16.4–43.1), median survival after SRS was 9.3 months (95% CІ 5.6–22.7). The majority of patients (72%) were alive for at least 6 months following SRS and about half of patients (48%) survived for at least 24 months following the resection of the primary tumor. OS and survival after SRS depend significantly on the extent of the surgical resection of the primary tumor. The addition of temozolomide to radiotherapy prolongs survival in GBM patients. The relapse time affected significantly OS (p = 0.00008), but not survival after SRS. Neither OS, nor survival after SRS were affected significantly by such factors as the age of patients, the number of SRS fractions (one fraction vs several fractions), and target volume. Conclusion: Radiosurgery improves the survival in patients with recurrent GBM. The extent of the surgical resection and adjuvant alkylating chemotherapy of the primary tumor, overall biologically effective dose and time between the primary diagnosis and SRS affect significantly the survival. The search for the more effective schedules for treating such patients requires further studies with more numerous cohorts of patients and extended follow-up.

References

Hanif F, Muzaffar K, Perveen K, et al. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 2017; 18: 3–9. doi: https://doi.org/10.22034/APJCP.2017.18.1.3

Aldoghachi AF, Aldoghachi AF, Breyne K, et al. Recent advances in the therapeutic strategies of glioblastoma multiforme. Neuroscience 2022; 491: 240–70. doi: https://doi.org/10.1016/j.neuroscience.2022.03.030

Koshy M, Villano JL, Dolecek TA, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 2012; 107: 207–12. doi: https://doi.org/10.1007/s11060-011-0738-7

Shidoh S, Savjani RR, Cho NS, et al. Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation. J Neurooncol 2022; 160: 115–25. doi: https://doi.org/10.1007/s11060-022-04123-3

Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021; 18: 170–86. doi: https://doi.org/10.1038/s41571-020-00447-z

Bräutigam E, Lampl C, Track C, et al. (2019). Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept. Clin Transl Oncol 2019; 21: 582–7. doi: https://doi.org/10.1007/s12094-018-1957-6

Birzu C, French P, Caccese M, et al. Recurrent glioblastoma: from molecular landscape to new treatment perspectives. Cancers 2020; 13: 47. doi: https://doi.org/10.3390/cancers13010047

Kazmi F, Soon YY, Leong YH, et al. Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol 2019; 142: 79–90. doi: https://doi.org/10.1007/s11060-018-03064-0

Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803–20. doi: https://doi.org/10.1007/s00401-016-1545-1

Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010; 76: S10–9. doi: https://doi.org/10.1016/j.ijrobp.2009.07.1754

Chen W, Wang Y, Zhao B, et al. Optimal therapies for recurrent glioblastoma: a Bayesian network meta-analysis. Front Oncol 2021; 11: 641878. doi: https://doi.org/10.3389/fonc.2021.641878

Minniti G, Niyazi M, Alongi F, et al. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol 2021; 16: 36. doi: https://doi.org/10.1186/s13014-021-01767-9

Schritz A, Aouali N, Fischer A, et al. Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma. Neurooncol Adv 2021; 3: vdab052. doi: https://doi.org/10.1093/noajnl/vdab052

Scoccianti S, Francolini G, Carta GA, et al. Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions. Crit Rev Oncol Hematol 2018; 126: 80–91. doi: https://doi.org/10.1016/j.critrevonc.2018.03.024

Zwirner K, Paulsen F, Schittenhelm J, et al. Prognostic parameters and outcome after re-irradiation for progressive glioblastoma. Acta Neurol Scand 2017; 136: 239–45. doi: https://doi.org/10.1111/ane.12719

Rades D, Witteler J, Leppert J, Schild SE. Re-irradiation for recurrent glioblastoma multiforme. Anticancer Res 2020; 40: 7077–81. doi: https://doi.org/10.21873/anticanres.14735

Griazov A, Glavatskyi O, Zemskova O, et al. Survival after stereotactic radiosurgery of recurrent glioblastomas in patients with radical resection of primary tumor. Ukr Sci Med Youth J 2022; 128: 57–73. doi: https://doi.org/10.32345/USMYJ.1(128).2022.57-73

Downloads

Published

07.03.2023

How to Cite

Glavatskyi, O., Griazov, A., Chuvashova, O., Kruchok, I., Griazov, A., Khmelnytskyi, H., … Zemskova, O. (2023). RADIOSURGICAL TREATMENT OF RECURRENT GLIOBLASTOMA AND PROGNOSTIC FACTORS AFFECTING TREATMENT OUTCOMES. Experimental Oncology, 46(4), 307–313. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-4.18920

Issue

Vol. 46 No. 4 (2024): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.